NCT06346080 Molecular Analysis for Gastro-Esophageal Cancer: Multicenter Discrete Choice Experiment
| NCT ID | NCT06346080 |
| Status | Recruiting |
| Phase | — |
| Sponsor | KU Leuven |
| Condition | Esophageal Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 2,200 participants |
| Start Date | 2024-08-01 |
| Primary Completion | 2026-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 2,200 participants in total. It began in 2024-08-01 with a primary completion date of 2026-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this survey is to investigate the participants' preference for a specific screening/diagnostic tool to detect and assess gastro-esophageal cancer. The main question it aims to answer are: * Which diagnostic modality is preferred by patients and the general population? * Which features of the diagnostic test are most detrimental in the decision-making for one or the other modality? * Are geographical differences present in regard to the preference for a diagnostic modality? Participants will be asked to complete a survey of 20-25min, including a brief intake regarding their socio-economic status. This approach will allow us to correct for confounding factors.
Eligibility Criteria
Inclusion Criteria: 1. Individuals \>18yo to 75yo (upper age limit of Barrett's surveillance) 2. Access to computer or smartphone 3. Clear understanding of available languages of the experiment (English, French, Dutch, Spanish, German, Chinese, Japanese) Exclusion Criteria: 1. Individuals less than 18yo and more than 75yo 2. Incarcerated individuals
Contact & Investigator
Stijn Vanstraelen, MD
PRINCIPAL INVESTIGATOR
UZ Leuven
Frequently Asked Questions
Who can join the NCT06346080 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Esophageal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06346080 currently recruiting?
Yes, NCT06346080 is actively recruiting participants. Contact the research team at stijn.vanstraelen@kuleuven.be for enrollment information.
Where is the NCT06346080 trial being conducted?
This trial is being conducted at Leuven, Belgium.
Who is sponsoring the NCT06346080 clinical trial?
NCT06346080 is sponsored by KU Leuven. The principal investigator is Stijn Vanstraelen, MD at UZ Leuven. The trial plans to enroll 2,200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.